nasdaq:aimt
|
6609212
|
Apr 14th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
148.00
|
Open
|
|
Apr 13th, 2024 10:31PM
|
Apr 14th, 2024 10:30AM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 13th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
148.00
|
Open
|
|
Apr 12th, 2024 10:22PM
|
Apr 13th, 2024 10:58AM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 12th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
149.00
|
Open
|
|
Apr 11th, 2024 10:25PM
|
Apr 12th, 2024 07:53AM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 11th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
149.00
|
Open
|
|
Apr 10th, 2024 10:44PM
|
Apr 11th, 2024 10:37AM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 10th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
149.00
|
Open
|
|
Apr 9th, 2024 10:29PM
|
Apr 10th, 2024 04:46PM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 9th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
150.00
|
Open
|
|
Apr 8th, 2024 10:39PM
|
Apr 9th, 2024 09:28AM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 8th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
150.00
|
Open
|
|
Apr 7th, 2024 10:49PM
|
Apr 8th, 2024 06:26PM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 7th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
150.00
|
Open
|
|
Apr 6th, 2024 10:38PM
|
Apr 6th, 2024 10:38PM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 6th, 2024 12:00AM
|
Aimmune Therapeutics
|
27K
|
150.00
|
Open
|
|
Apr 5th, 2024 10:37PM
|
Apr 5th, 2024 10:37PM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:aimt
|
6609212
|
Apr 5th, 2024 12:00AM
|
Aimmune Therapeutics
|
26K
|
152.00
|
Open
|
|
Apr 4th, 2024 10:43PM
|
Apr 4th, 2024 10:43PM
|
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies.
Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.
**The information on Aimmune’s LinkedIn channel – including any product information - is intended for U.S. residents only and is governed by applicable U.S. laws and regulations. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
|
Open
|
Food Allergies, Desensitization, Oral Immunotherapy, and Drug Development
|
Open
|
8000 Marina Boulevard,
|
Brisbane
|
CA
|
US
|
94005-1884
|
|
Aimmune Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|